Radioimmunotherapy – still experimental? Rational, proven indications and future trends

Review

Summary

With the increasing incidence of Non-Hodgkin's lymphoma and still substantial disease related mortality, further improvement of therapeutic options is needed. Radioimmunotherapy (RIT) is a targeted treatment with the potential to augment the efficacy of conventional monoclonal antibodies. Out of numerous antibody – radioisotype combinations two have been approved so far: 90Y-Ibritumumab tiuxetan and 131I-Tositumomab. The tolerability of the drugs is excellent and the main side effect is protracted cytopaenia, which occurs 4–8 weeks after the treatment. Limitations of use are reduced bone marrow reserve, higher bone marrow involvement and preceding extensive radiotherapy. Results of initial trials showed promising phase I/II data for a variety of lymphoma entities. Especially in follicular lymphoma subsequent phase II/III studies now have established these drugs as single agent treatment for relapsed disease, with improved response rates when applied at an earlier disease stage. The recently released results of the so-called FIT trial helped us to additionally establish their role as consolidation treatment immediately after preceding cyclic chemotherapy. Current concepts evaluate the benefit of RIT in the context of Rituximab maintenance therapy and high dose therapy. In aggressive lymphoma, clinical efficacy of single agent treatment has been found, but nevertheless the development of the drugs in the context of consolidation treatment or as part of high dose regimens is favoured now. Upcoming results will help to identify the potential of these drugs when applied in entities like mantle cell lymphoma, diffuse large cell lymphoma or marginal zone lymphoma. Taken together, radioimmunotherapy is increasingly part of multimodal treatment algorithms, rather than a substitute for other treatment options. Moreover, given their side effect profile, radioimmunoconjugates are a highly attractive single agent option for patients with restrictions against other anti-lymphoma therapies.

Keywords

Non-Hodgkin's lymphoma Radioimmunotherapy Ibritumomab tiuxetan Tositumomab 

References

  1. Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood, 80: 1502–1510, 1992PubMedGoogle Scholar
  2. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood, 84: 2457–2466, 1994PubMedGoogle Scholar
  3. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res, 40: 3147–3154, 1980PubMedGoogle Scholar
  4. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood, 69: 584–591, 1987PubMedGoogle Scholar
  5. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med, 6: 443–446, 2000PubMedCrossRefGoogle Scholar
  6. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22: 7359–7368, 2003PubMedCrossRefGoogle Scholar
  7. Stockmeyer B, Dechant M, van Egmond M, et al. Triggering FC{alpha}-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy. J Immunol, 165: 5954–5961, 2000PubMedGoogle Scholar
  8. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers, 2: 49–53, 1987PubMedGoogle Scholar
  9. Deshpande SV, DeNardo SJ, Meares CF, et al. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med, 29: 217–225, 1988PubMedGoogle Scholar
  10. DeNardo GL, Lamborn KR, Goldstein DS, Kroger LA, DeNardo SJ. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Cancer, 80: 2706–2711, 1997PubMedCrossRefGoogle Scholar
  11. O'Donnell RT, DeNardo GL, Kukis DL, et al. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med, 40: 2014–2020, 1999PubMedGoogle Scholar
  12. DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm, 13: 239–254, 1998PubMedCrossRefGoogle Scholar
  13. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol, 16: 3246–3256, 1998PubMedGoogle Scholar
  14. DeNardo GL, Schlom J, Buchsbaum DJ, et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer, 94: 1332–1348, 2002PubMedCrossRefGoogle Scholar
  15. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346: 235–242, 2002PubMedCrossRefGoogle Scholar
  16. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol,17: 268–276, 1999PubMedGoogle Scholar
  17. Hiddemann W, Dreyling M, Forstpointner R, et al. Combined immunochemotherpy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood, 102: 352a, 2003Google Scholar
  18. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol, 16: 2825–2833, 1998PubMedGoogle Scholar
  19. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol, 26: 79-87, 1999PubMedGoogle Scholar
  20. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood, 20062006-05-021113-2006Google Scholar
  21. Nadler LM, Ritz J, Hardy R, et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest, 67: 134–140, 1981PubMedCrossRefGoogle Scholar
  22. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17: 3793–3803, 1999PubMedGoogle Scholar
  23. Czuczman M, Emmanouilides C, Witzig T, et al. Multivariante analysis of prognostic factors correlated with response to 90Y-ibritumomab tiuxetan radioimmunotherapy for non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol (Meeting Abstracts), 21: 1062, 2002Google Scholar
  24. Jacobs SA, Vidnovic N, Joyce J, et al. Full-dose 90Y Ibritumomab Tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res, 11: 7146s–7150s, 2005PubMedCrossRefGoogle Scholar
  25. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259–1266, 2000PubMedGoogle Scholar
  26. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med, 44: 465–474, 2003PubMedGoogle Scholar
  27. Conti PS, White C, Pieslor P, et al. The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (Zevalin) regimen: results from a Zevalin Imaging Registry. J Nucl Med, 46: 1812–1818, 2005PubMedGoogle Scholar
  28. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17: 3793–3803, 1999PubMedGoogle Scholar
  29. Wiseman GA, Gordon LI, Multani PS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 99: 4336–4342, 2002PubMedCrossRefGoogle Scholar
  30. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med, 27: 766–777, 2000PubMedCrossRefGoogle Scholar
  31. Kaminski MS, Tuck M, Estes J, et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 352: 441–449, 2005PubMedCrossRefGoogle Scholar
  32. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 18: 1316–1323, 2000PubMedGoogle Scholar
  33. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20: 2453–2463, 2002PubMedCrossRefGoogle Scholar
  34. Emmanouilides C, Witzig TE, Wiseman GA, et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 22: 684–691, 2007PubMedCrossRefGoogle Scholar
  35. Witzig TE, White CA, Gordon LI, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol, 21: 1263–1270, 2003PubMedCrossRefGoogle Scholar
  36. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med, 329: 459–465, 1993PubMedCrossRefGoogle Scholar
  37. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259–1266, 2000PubMedGoogle Scholar
  38. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259–1266, 2000PubMedGoogle Scholar
  39. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 18: 1316–1323, 2000PubMedGoogle Scholar
  40. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 19: 3918–3928, 2001PubMedGoogle Scholar
  41. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed Non-Hodgkin's Lymphomas. J Clin Oncol, 23: 7565–7573, 2005PubMedCrossRefGoogle Scholar
  42. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 19: 3918–3928, 2001PubMedGoogle Scholar
  43. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17: 3793–3803, 1999PubMedGoogle Scholar
  44. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood, 103: 4429–4431, 2004PubMedCrossRefGoogle Scholar
  45. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20: 2453–2463, 2002PubMedCrossRefGoogle Scholar
  46. Emmanouilides C, Witzig TE, Gordon LI, et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma, 47: 629–636, 2006PubMedCrossRefGoogle Scholar
  47. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer, 109: 1804–1810, 2007PubMedCrossRefGoogle Scholar
  48. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20: 3262–3269, 2002PubMedCrossRefGoogle Scholar
  49. Horning SJ, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol, 23: 712–719, 2005PubMedCrossRefGoogle Scholar
  50. Ogura M, Morishima Y, Watanabe T, et al. 90Y Ibritumomab tiuxetan (Y2B8, Zevalin(R) radioimmunotherapy/RIT) is highly effective for relapsed or refractory indolent B-cell non-Hodgkin's lymphoma B-NHL) retreated eith rituximab-containing chemotherapy (R-Chemo): Japanese multicenter phase II study [abstract]. Blood, 108: Abstract 2767 ASH 2006Google Scholar
  51. Davies AJ, Rohatiner AZ, Howell S, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 22: 1469–1479, 2004PubMedCrossRefGoogle Scholar
  52. Kaminski MS, Tuck M, Estes J, et al. 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. N Engl J Med, 352: 441–449, 2005PubMedCrossRefGoogle Scholar
  53. Sweetenham JW, Dicke K, Arcaroli J, et al. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin(R)) Therapy with Rituximab Maintenance in Patients with Untreated Low-Grade Follicular Lymphoma. ASH Annual Meeting Abstracts, vol. 104. p. 2633, 2004Google Scholar
  54. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol, 19: 3918–3928, 2001PubMedGoogle Scholar
  55. Emmanouilides C. Radioimmunotherapy for non-hodgkin lymphoma: historical perspective and current status. J Clin Exp Hematop, 47: 43–60, 2007PubMedCrossRefGoogle Scholar
  56. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20: 3262–3269, 2002PubMedCrossRefGoogle Scholar
  57. Leonard JP, Coleman M, Kostakoglu L, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol, 23: 5696–5704, 2005PubMedCrossRefGoogle Scholar
  58. Link B, Kaminski MS, Coleman M, Leonard J. Phase II study of CVP followed by tositumomab and iodine I 131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL) [abstract]. J Clin Oncol (Meeting Abstracts), 22: Abstract 6520, 2004Google Scholar
  59. Shipley DL, Spigel DR, Carrel DL, Dannaher C, Greco FA. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: a minnie pearl cancer research network phase ii trial [abstract]. J Clin Oncol (Meeting Abstracts), 22: Abstract 6519, 2004Google Scholar
  60. Press OW, Unger JM, Braziel RM, et al. Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: five-Year follow-up of southwest oncology group protocol S9911. J Clin Oncol, 24: 4143–4149, 2006PubMedCrossRefGoogle Scholar
  61. Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol, 9: 352–358, 2008.PubMedCrossRefGoogle Scholar
  62. Hagenbeek A, Bischof-Delaloye A, Radford JA, et al. 90Y-Ibritumomab Tiuxetan (Zevalin(R)) Consolidation of First Remission in advanced stage follicular non-Hodgkin's lymphoma: first results of the international randomized phase 3 First-Line Indolent Trial (FIT) in 414 Patients. ASH Annual Meeting Abstracts, vol. 110. p. 643, 2007Google Scholar
  63. Goff L, Summers K, Iqbal S, et al. Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan (Zevalin(R)) as Consolidation of First Remission in Patients with Advanced Stage Follicular Lymphoma: A 'Real-Time' MBR RQ-PCR Analysis. ASH Annual Meeting Abstracts, vol. 110. p. 3412, 2007Google Scholar
  64. Gondek K, Shah S, Bischof-Delaloye A, et al. Health-related quality of life in patients with advanced-stage follicular lymphoma receiving consolidation with 90Y-Ibritumomab Tiuxetan (Zevalin(R)) of first remission: results from the randomized phase 3 First-Line Indolent Trial (FIT). ASH Annual Meeting Abstracts, vol. 110. p. 3319, 2007Google Scholar
  65. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol, 21: 3918–3927, 2003PubMedCrossRefGoogle Scholar
  66. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood, 102: 2351–2357, 2003PubMedCrossRefGoogle Scholar
  67. Nademanee A, Molina A, Dagis A, et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma, 1: 46–54, 2000PubMedCrossRefGoogle Scholar
  68. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood, 106: 2896–2902, 2005PubMedCrossRefGoogle Scholar
  69. Gisselbrecht C, Decaudin D, Mounier N, et al. 90Yttrium Ibritumomab Tiuxetan (Zevalin) Combined with BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Follicular Lymphoma. GELA Phase II Study. ASH Annual Meeting Abstracts, vol. 110. p. 22, 2007Google Scholar
  70. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17: 3793–3803, 1999PubMedGoogle Scholar
  71. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood, 110: 54–58, 2007PubMedCrossRefGoogle Scholar
  72. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol, 19: 769–773, 2008PubMedCrossRefGoogle Scholar
  73. Hamlin PA, Moskowitz C, Wegner T, et al. Sequential R-CHOP and yttrium-90 ibritumumab tiuxetan is a highly effective regimen for high risk elderly patients with untreated DLCBL [abstract]. 10th Int. Conference on Malignant Lympohma, Lugano, Switzerland, 2008Google Scholar
  74. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333: 1540–1545, 1995PubMedCrossRefGoogle Scholar
  75. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol, 16: 3270–3278, 1998PubMedGoogle Scholar
  76. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med, 329: 1219–1224, 1993PubMedCrossRefGoogle Scholar
  77. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]-tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol, 25: 1396–1402, 2007PubMedCrossRefGoogle Scholar
  78. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood, 96: 2934–2942, 2000PubMedGoogle Scholar
  79. Vanazzi A, Ferrucci PF, Grana C, et al. High Dose 90Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study. ASH Annual Meeting Abstracts, vol. 108. p. 2720, 2006Google Scholar
  80. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin's lymphoma. Blood, vol. 106. p. 2896–2902, 2005PubMedCrossRefGoogle Scholar
  81. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of Yttrium-90 Ibritumomab Tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol, 26: 90–95, 2008PubMedCrossRefGoogle Scholar
  82. Khouri IF, Saliba RM, Hosing C, et al. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL). ASH Annual Meeting Abstracts, vol. 108. p. 315, 2006Google Scholar
  83. Gopal AK, Rajendran JG, Pagel JM, et al. A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL). ASH Annual Meeting Abstracts, vol. 108. p. 316, 2006Google Scholar
  84. Gisselbrecht C, Bethge W, Duarte RF, et al. Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant, 40: 1007–1017, 2007PubMedCrossRefGoogle Scholar
  85. Gopal AK, Pagel JM, Rajendran JG, et al. Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. Biol Blood Marrow Transplant, 12: 697–702, 2006PubMedCrossRefGoogle Scholar
  86. Oki Y, Pro B, Delpassand E, et al. A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin(R)) for treatment of patients with relapsed and refractory Mantle Cell Lymphoma (MCL). ASH Annual Meeting Abstracts, vol. 104. p. 2632, 2004Google Scholar
  87. Jurczak W, Giza A, Zimowska-Curylo D, et al. 90Y-Zevalin(R) (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation in Mantle Cell Lymphoma (MCL) Patients, Not Illegible for Intensive Therapy Protocols. ASH Annual Meeting Abstracts, vol. 110. p. 4497, 2007Google Scholar
  88. Weigert O, von Schilling C, Rummel MJ, et al. Efficacy and Safety of a Single-Course of Yttrium-90 Ibritumomab Tiuxetan for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma after/not appropriate for autologous stem cell transplantation – final analysis of a phase II trial of the European MCL network. ASH Annual Meeting Abstracts, vol. 110. p. 4501, 2007Google Scholar
  89. Weigert O, von Schilling C, Rummel MJ, et al. Efficacy and safety of a single-course of Yttrium-90 Ibritumomab Tiuxetan for treatment of patients with relapsed or refractory mantle cell lymphoma after/not appropriate for autologous stem cell transplantation – final analysis of a phase II trial of the European MCL Network. ASH Annual Meeting Abstracts, 110: 4501, 2007Google Scholar
  90. Smith MR, Chen H, Gordon L, et al. Phase II study of situximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1499) [abstract]. J Clin Oncol, 24, 2006Google Scholar
  91. Jurczak W, Giza A, Szostek M, et al. 90Y-Zevalin(R) (90Y-Ibritumomab Tiuxetan) Radioimmunotherapy (RIT) Consolidation of FCM Induction Chemotherapy in Mantle Cell Lymphoma (MCL) Patients: Results from the PLRG upon Completed Enrollment. ASH Annual Meeting Abstracts, vol. 108. p. 2747, 2006Google Scholar
  92. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood, 99: 3158–3162, 2002PubMedCrossRefGoogle Scholar
  93. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. J Clin Oncol, 24: 4418–4425, 2006PubMedCrossRefGoogle Scholar
  94. Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer, 112: 856–862, 2008PubMedCrossRefGoogle Scholar
  95. Steinhoff M, Gellrich S, Maza S, et al. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results [abstract]. J Clin Oncol, 8(26)Google Scholar
  96. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer, 110: 2528–2534, 2007PubMedCrossRefGoogle Scholar
  97. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin's lymphoma treated with Tositumomab and Iodine I 131 Tositumomab (BEXXAR(R)). Blood, 105: 4576–4582, 2005PubMedCrossRefGoogle Scholar
  98. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol, 25: 4285–4292, 2007PubMedCrossRefGoogle Scholar
  99. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20: 3262–3269, 2002PubMedCrossRefGoogle Scholar
  100. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol, 20: 3885–3890, 2002PubMedCrossRefGoogle Scholar
  101. Dosik AD, Coleman M, Kostakoglu L, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer, 106: 616–622, 2006PubMedCrossRefGoogle Scholar
  102. Bishton MJ, Leahy MF, Hicks RJ, et al. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab. Ann Oncol, 19(9): 1629–1633, 2008PubMedCrossRefGoogle Scholar
  103. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259–1266, 2000PubMedGoogle Scholar
  104. Kaminski MS, Radford JA, Gregory SA, et al. Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's lymphoma who had previously responded to I-131 Tositumomab. J Clin Oncol, 23: 7985–7993, 2005PubMedCrossRefGoogle Scholar
  105. Shah J, Harrough D, Saville W, et al. Safety and efficacy of retreating follicular non-Hodgkin's lymphoma (NHL) with 90Y ibritumomab tiuxetan. J Clin Oncol (Meeting Abstracts), 24: 17528, 2006Google Scholar
  106. Justice TE, Martenson JA, Wiseman GA, Witzig TE. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer, 107: 433–438, 2006PubMedCrossRefGoogle Scholar
  107. Jankowitz RC, Foon KA, DeMonaco NA, et al. Phase II study of short course CHOP-rituximab (R) followed by ibritumomab tiuxetan (IT) as first-line treatmentfor follicular lymphoma (FL) [abstract]. J Clin Oncol, 25: 8005, 2007Google Scholar
  108. Shipley DL, Spigel DR, Carrel DL, Dannaher C, Greco FA. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A minnie pearl cancer research network phase ii trial. [abstract]. J Clin Oncol (Meeting Abstracts), 22: Abstract 6519, 2004Google Scholar
  109. DeMonaco NA, Wu M, Osborn J, et al. Phase II trial of abbreviated CHOP-Rituximab followed by 90Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in patients with previously-untreated follicular Non-Hodgkin Lymphoma (NHL). Blood, 106: Abstract 2449, 2005Google Scholar
  110. Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res, 11: 5215–5222, 2005PubMedCrossRefGoogle Scholar
  111. Illidge TMBMCZMDYLVPJW. Phase I/II study of fractionated radioimmuntherapy (RIT) in relapsed low grade Non-Hodgkin's Lymphoma (NHL) [abstract]. Blood, Abstract: Abstract ASH 2004Google Scholar
  112. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol, 21: 3051–3059, 2003PubMedCrossRefGoogle Scholar
  113. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res, 10: 5327–5334, 2004PubMedCrossRefGoogle Scholar
  114. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol, 23: 5044–5051, 2005PubMedCrossRefGoogle Scholar
  115. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res, 9: 3982S–3990S, 2003PubMedGoogle Scholar
  116. Kraeber-Bodere, F., Morschhauser F, et al. Fractionated radioimmunotherapy in NHL with DOTA-conjugated epratuzumab: Results at high cumulative dose of 90Y [abstract]. J Clin Oncol, 26: Abstract 8502, 2008Google Scholar
  117. Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and Iodine-131 Tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol, 23: 7565–7573, 2005PubMedCrossRefGoogle Scholar
  118. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol, 17: 3793–3803, 1999PubMedGoogle Scholar
  119. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol, 20: 2453–2463, 2002PubMedCrossRefGoogle Scholar
  120. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 20: 3262–3269, 2002PubMedCrossRefGoogle Scholar
  121. Kaminski MS, Tuck M, Estes J, et al. 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. N Engl J Med, 352: 441–449, 2005PubMedCrossRefGoogle Scholar
  122. Kaminski MS, Radford JA, Gregory SA, et al. Re-Treatment With I-131 Tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 Tositumomab. J Clin Oncol, 23: 7985–7993, 2005PubMedCrossRefGoogle Scholar
  123. Press OW, Unger JM, Braziel RM, et al. Phase II Trial of CHOP Chemotherapy followed by Tositumomab/Iodine I-131 Tositumomab for Previously untreated follicular non-Hodgkin's lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911. J Clin Oncol, 24: 4143–4149, 2006PubMedCrossRefGoogle Scholar
  124. Hagenbeek A, Bischof-Delaloye A, Radford JA, et al. 90Y-Ibritumomab Tiuxetan (Zevalin(R)) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin's Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients. ASH Annual Meeting Abstracts, vol. 110. p. 643, 2007Google Scholar
  125. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation. Blood, 110: 54–58, 2007PubMedCrossRefGoogle Scholar
  126. Gisselbrecht C, Decaudin D, Mounier N, et al. 90Yttrium Ibritumomab Tiuxetan (Zevalin) Combined with BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Follicular Lymphoma. GELA Phase II Study. ASH Annual Meeting Abstracts, vol. 110. p. 22, 2007Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of Haematology/OncologyJohannes Gutenberg-UniversityMainzGermany

Personalised recommendations